Study to See How Well an Eye Drop, SURF-201, Works and What Side Effects There Are in Cataract Surgery Subjects

Post-surgical Ocular Inflammation Clinical Trial

Official title:
A Multicenter, Randomized, Double-Masked Study To Compare The Ocular Safety, Tolerability, And Efficacy Of A Topical 0.2% Ophthalmic Corticosteroid Solution (SURF-201) To Vehicle In Cataract Surgery Subjects

Status Completed

Clinical Trial Summary

SURF-201 is being studied for the treatment of eye inflammation and pain in people who are undergoing cataract surgery. SURF-201 is an investigational drug (which means the study drug is currently being tested) in the form of a sterile eye drop. The purpose of this research study is to see how well SURF-201 works and what side effects there are, and to compare it with Vehicle (placebo). This study will involve about 80 study participants at several different research sites in the United States.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Cataract
Inflammation
Post-surgical Ocular Inflammation
Post-surgical Ocular Pain

Clinical Trial Details

NCT number	NCT04324359
Study type	Interventional
Source	Surface Ophthalmics, Inc.
Contact
Status	Completed
Phase	Phase 2
Start date	March 3, 2020
Completion date	November 20, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02736175` - OTX-15:003: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery	Phase 3
Recruiting	`NCT04592081` - Dextenza Within Upper Lid Canaliculus Compared With Lower Lid Canaliculus Following Bilateral Cataract Extraction Surgery With PCIOL.	Phase 4
Completed	`NCT02089113` - OTX-14-003: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery	Phase 3